FTLF: FitLife Brands, Inc. Stock

by  •  • Comments Off on FTLF: FitLife Brands, Inc. Stock

SIC 2833 – Medicinal Chemicals and Botanical Products

Valuation
Market Cap ($M) 122.98
Enterprise Value ($M) 131.56
Book Value ($M) 36.13
Book Value / Share 3.92
Price / Book 3.40
NCAV ($M) -4.26
NCAV / Share -0.46
Price / NCAV -28.85

Profitability (mra)
Return on Invested Capital (ROIC) 0.18
Return on Assets (ROA) 0.16
Return on Equity (ROE) 0.31

Liquidity (mrq)
Quick Ratio 0.62
Current Ratio 1.60

Balance Sheet (mrq) ($M)
Current Assets 18.14
Assets 58.53
Liabilities 22.41
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 64.47
Operating Income 13.37
Net Income 8.98
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 9.61
Cash from Investing -0.01
Cash from Financing -6.98

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Askeladden Capital Management Llc 5.40

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Fiscal Year Ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTI
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-04-21 1,449 10,994 13.18
2025-04-17 4,395 35,693 12.31
2025-04-16 1,600 4,772 33.53

(click for more detail)

Similar Companies
FBRX – Forte Biosciences, Inc. FENC – Fennec Pharmaceuticals Inc.
FLGC – Flora Growth Corp. GALT – Galectin Therapeutics Inc.
GDTC – CytoMed Therapeutics Limited


Financial data and stock pages provided by
Fintel.io